Latham & Watkins Advises Seres Therapeutics in SER-109 Co-Commercialization License Agreement with Nestlé Health

Multidisciplinary team advises the microbiome therapeutics company in the licensing transaction.

July 01, 2021

Seres Therapeutics, Inc. (Nasdaq:MCRB), a leading microbiome therapeutics company, has announced that it has entered into an agreement with Nestlé Health Science to jointly commercialize SER-109, Seres’ investigational oral microbiome therapeutic for recurrent Clostridium difficile infection (CDI), in the United States (US) and Canada. If approved, SER-109 would become the first ever FDA approved microbiome therapeutic.

Latham & Watkins LLP represents Seres Therapeutics, Inc. in the license agreement with a team led by Bay Area partner Judith Hasko, with Bay Area associate Peggy Ni and New York associate Jiqiang Lin. Corporate aspects of the transaction were led by Boston/New York partner Peter Handrinos, with London/Boston associate Nicole McNeil and Boston associate Jennifer Yoon.

Advice was also provided on tax matters by Bay Area partner Kirt Switzer, with Bay Area associates Jessica Chen and Derek Gumm; and on intellectual property matters by Washington, D.C. partner Jeremiah Wolsk.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.